Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Go to the ORD website
Go to the QUERI website

COVID-19 Post-acute Care Major Organ Damage: A Living Rapid Review

Click for list of published reports
Click for topic nomination form
Click for list of reports in progress

Subscribe to the
ESP Report RSS feed RSS feed icon
COVID-19 Post-acute Care Major Organ Damage: A Living Rapid Review

Prepared by:
Evidence Synthesis Program (ESP) Center
Minneapolis VA Health Care System
Minneapolis, MN
Timothy J. Wilt, MD, MPH, Director
Wei Duan-Porter, MD, PhD, Associate Director

Recommended citation:
Greer N, Bart B, Billington C, Diem SJ, Ensrud KE, Kaka A, Klein M, Melzer A, Reule S, Shaukat A, Sheets K, Starks J, Vardeny O, McKenzie L, Duan-Porter W, Wilt, TJ. COVID-19 Post-acute Care Major Organ Damage: A Living Rapid Review. Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; 2020.



Download PDF: Complete Report, Report, Appendices, Evidence Snapshot

Background

The purpose of this living rapid review is to determine the prevalence of post-acute care major organ damage and healthcare or service use needs associated with major organ damage in adults who were hospitalized with or for COVID-19. The topic was nominated by the VA Evidence Synthesis Program Coordinating Center in collaboration with VHA clinical and operations partners in order to guide future clinical care decisions and resource needs related to COVID-19. It is 1 in a series of 3 living rapid reviews conducted across VA ESP sites addressing post-acute care prevalence related to: 1) mental health, 2) rehabilitation/functional status, and 3) major organ damage in patients hospitalized with or for COVID-19.

Key Questions

1. What is the post- acute care prevalence of major organ damage among adults hospitalized with or for proven COVID-19 disease?

2. Does the post-acute care prevalence of major organ damage among adults with or for COVID-19 disease vary by patient characteristics (eg, age, sex, race/ethnicity, preexisting co-morbidities/frailty, place of residence), COVID-19 disease severity, or other factors (eg, treatment for COVID-19)?

3. What are the short- (< 3 months) and long-term (> 3 months) healthcare or service use needs of adults surviving COVID-19 disease with major organ damage?


Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.